Establishment and characterization of a new human erythroleukemic cell line, ERY-1.
The growth factor-independent erythroleukemic cell line ERY-1 was established from the peripheral blood of a 87-year-old woman with chronic myeloid leukemia (CML) in the acute phase. Immunophenotyping showed that fresh leukemic cells were positive for CD13, CD33, CD36 and CD235a (glycophorin A), a phenotype compatible with that of erythroblastic cells. Cytogenetic and fluorescence in situ hybridization (FISH) analysis demonstrated classical t(9;22)(q34;q11) chromosomic translocation associated with a duplication of the BCR-ABL fusion gene. Other cytogenetic abnormalities were detected in all analyzed mitosis, the most frequent being a trisomy of chromosome 8. The established ERY-1 cell line retains these immunophenotypic and cytogenetic features, and light and electron microscopy confirmed the relatively mature erythroblastic phenotype of the cells. In addition, ERY-1 cell line expressed beta-globin mRNA and a non-phosphorylable form of the erythropoietin receptor, even in presence of erythropoietin. Of note, the proliferation of ERY-1 cells was inhibited by TGFbeta1 or STI-571 (Gleevec), without significant induction of further differentiation. In conclusion, ERY-1 is a new growth factor-independent human erythroleukemic cell line with a relatively mature phenotype that may be useful to study the molecular events involved in erythroblastic differentiation.
Ribadeau Dumas
Antoine
A
Unité CNRS UMR 8147, Faculté de Pharmacie et Hôpital Necker 4, Avenue de l'Observatoire 75006, Paris, France.
Hamouda
Nadine Ben
NB
Leriche
Laurence
L
Piffaut
Marie-Claude
MC
Bonnemye
Patrick
P
Kuen
René Lai
RL
Tricottet
Viviane
V
Merle-Beral
Hélène
H
N'Guyen Khac
Florence
F
Arock
Michel
M
D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D001549:Benzamides; D045744:Cell Line, Tumor; D002898:Chromosomes, Human, Pair 8; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D020440:Gene Duplication; D005914:Globins / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D010641:Phenotype; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D017467:Receptors, Erythropoietin / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D053773:Transforming Growth Factor beta1; D014178:Translocation, Genetic; D014314:Trisomy
D015703:Antigens, CD; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D017467:Receptors, Erythropoietin; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000068877:Imatinib Mesylate; D005914:Globins; D016044:Fusion Proteins, bcr-abl